NCT01773070View on ClinicalTrials.gov

A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study

PHASE3CompletedINTERVENTIONAL

Enrollment

478

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Hepatitis C

Interventions

DRUG

ABT-450/ritonavir

ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.

DRUG

ABT-333

Drug is not administered -- this study is follow-up for participants previously receiving the drug.

DRUG

ABT-267

Drug is not administered -- this study is follow-up for participants previously receiving the drug.

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01773070 - A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study | Biotech Hunter | Biotech Hunter